《大行》高盛:翰森制药(03692.HK)Ris-rez三期研究获强劲验证 安全性及更早线扩展成焦点

阿斯达克财经
Yesterday

高盛发表报告指,翰森制药(03692.HK) 日前发表靶向B7-H3抗体偶联药物(ADC)Ris-Rez中国三期研究数据,在治疗复发小细胞肺癌(SCLC)中展现统计学显著及临床有意义的总生存期(OS)获益,中位OS为18.5个月对10.3个月,风险比(HR)为0.46。高盛指出结果令人鼓舞,为迄今二线SCLC标准治疗及在研竞争候选药物之中,录得的最佳OS获益,预期数据将为其中国监管审批提供支持,并...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10